Uses of kinase inhibitors for inducing and maintaining pluripotency
AssigneesWhitehead Institute for Biomedical Research, Dana-Farber Cancer Institute, Inc.
InventorsThorold W. Theunissen, Nathanael S. Gray, Rudolf Jaenisch
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compounds of any one of Formulae (A) to (L). The present disclosure also provides compositions, uses, and methods that include or involve a compound described herein, a serine/threonine-protein kinase B-Raf (BRAF) inhibitor, an epidermal growth factor receptor (EGFR) inhibitor, a vascular endothelial growth factor 1 (VEGFR1) inhibitor, a fibroblast growth factor receptor 1 (FGFR1) inhibitor, or a combination thereof. The compounds, compositions, uses, and methods are useful in changing the pluripotency state of a vertebrate cell to a more nave state.
Claims25
A method for changing the pluripotency state of a human cell to a more naîve state, the method comprising:
- culturing a pluripotent human cell in the presence of (i) a serine/threonine-protein kinase B-Raf (BRAF) inhibitor, (ii) a mitogen-activated protein kinase kinase (MEK) inhibitor, (iii) a rho-associated protein kinase (ROCK) inhibitor, and (iv) a proto-oncogene tyrosine-protein kinase (Src) inhibitor;
- and
- maintaining the cell in culture under conditions suitable and a time sufficient to convert the pluripotency state of the human cell to a more naïve state than the pluripotency state of the human cell of the culturing step.
(canceled)
4-183. (canceled)
185-186. (canceled)
191-199. (canceled)
Dependencies are inferred from the claim text.